Business Context and Reporting Period
Company: Gain Therapeutics, Inc. (GANX)
Filing Type: Form 8-K (Current Report)
Date of Report: May 26, 2026
Event: Disclosure of interim clinical and biomarker data from Part 2 (nine-month extension) of the Phase 1b open-label clinical study of GT-02287 in patients with Parkinson's disease (PD), with or without a GBA1 mutation.
Key Financial Metrics
This filing is a Current Report (Form 8-K) focused on clinical trial updates and does not contain financial statements. The filing text does not provide values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Clinical Data
- Study Continuation: A Data Monitoring Committee meeting on March 5, 2026, concluded the study should continue without changes. All 16 participants who entered the extension remain on study and have completed five months (Day 150) of dosing.
- Biomarker Results (Day 90):strong> In participants with elevated baseline cerebrospinal fluid (CSF) glucosylsphingosine (GluSph), levels decreased by an average of 81%. Levels of DOPA decarboxylase (DDC) also decreased in individuals with high baseline CSF GluSph.
- Clinical Scores (Day 150):strong> MDS-UPDRS scores remained stable and durable across the overall population. Participants with elevated baseline GluSph showed greater benefit than those with low baseline GluSph, with a 4.8-point difference in the sum of MDS-UPDRS Part II and Part III scores.
- Perceived Benefits: Unsolicited reports after 90 days included improved sense of smell/taste (4 instances), improved balance/gait (4 instances), and improved sleep (3 instances).
Outlook and Management Commentary
Management indicated that the data supports the continued development of GT-02287 for Parkinson's disease. The planned Phase 2 clinical trial is anticipated to include specific endpoints to further assess treatment effects, including the University of Pennsylvania Smell Identification Test (UPSIT) and Opal wearable sensors for in-clinic gait assessments.
Investor Verification Checklist
- Verify the full text of the oral presentation at the 3rd International GBA1 Meeting 2026 for detailed statistical analysis of the 4.8-point MDS-UPDRS difference.
- Confirm the timeline and design of the upcoming Phase 2 clinical trial, specifically regarding the inclusion of UPSIT and wearable sensor endpoints.
- Review the company's cash runway and capital requirements, as this filing does not disclose financial liquidity or funding status.
- Monitor future filings for any updates on the safety profile of GT-02287 as the nine-month extension progresses beyond Day 150.